Pomerantz LLP is investigating potential claims on behalf of investors of Certara, Inc. regarding possible violations of federal securities laws. The investigation concerns whether Certara and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. This inquiry follows recent disclosures about financial performance and strategic shifts that negatively impacted the company's stock price.

On May 11, 2026, Certara reported its first quarter 2026 financial results, revealing a decline in key operational metrics. Services revenue fell 4% year-over-year to $57.2 million, while services bookings dropped 14% year-over-year to $66.6 million. The company attributed the softer performance to challenges with Tier 1 customers in Model-Informed Drug Development (MIDD) services and described services performance as "mixed." Additionally, Certara announced its exit from the regulatory business within its services segment. In response to a question regarding consistency between software and services performance, the company stated that there had been "a lot of inconsistency and back and forth" over the last several quarters.

Following the earnings announcement, Certara's stock price declined sharply. The price of Certara shares fell by $1.18 per share, or approximately 19%, declining from $6.31 per share on May 8, 2026 to close at $5.13 per share on May 11, 2026.

Subsequently, on June 17, 2026, Certara announced that John Gallagher, the Company's Chief Financial Officer, had notified Certara of his intent to resign from his office effective as of the end of the day on July 14, 2026. On this news, Certara's stock price fell $0.49 per share, or 8.13%, to close at $5.54 per share on June 18, 2026.

The table below summarizes the key financial figures disclosed by Certara for the first quarter of 2026:

Pomerantz LLP is examining whether these disclosures were handled in compliance with federal securities regulations. Investors who purchased Certara securities and suffered losses are invited to join the investigation. To discuss their legal rights, investors may contact Danielle Peyton at 646-581-9980, ext. 7980 or via email at newaction@pomlaw.com . There is no cost or obligation to participate.

Certara, Inc. has appointed Faiz Mohammed as Interim Chief Financial Officer, effective July 14, 2026, following the resignation of Chief Financial Officer John Gallagher. The company has affirmed its 2026 financial guidance, keeping projections unchanged from the initial outlook provided during the first quarter earnings call on May 11, 2026. Certara has engaged a leading executive search firm to identify a permanent successor to the CFO role.

Management Transition Details

Mr. Mohammed, Senior Vice President of Finance and Treasurer, has served as a finance leader with Certara since 2018. He brings more than 25 years of senior finance and accounting experience across public and private equity-backed companies to the interim role.

Certara operates as a global leader in model-informed drug development, transforming drug discovery and development by assisting scientists and clinical teams in generating regulatory-grade evidence faster. Its solutions integrate biosimulation, clinical intelligence, and regulatory science into the workflows of drug developers worldwide. The company's client base includes more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies.